KDM1A and sickle cell disease: Importantly, promising results have been recently reported for the first Phase I clinical trial testing an inhibitor of KDM1 in acute leukemia [41], and additional clinical trials for KDM1 inhibitors on sickle cell disease, small cell lung cancer, and other advanced malignancies have been recently launched (NCT02712905, NCT02913443 and NCT03132324, https://clinicaltrials.gov).